Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 195,085 shares of CRSP, which is worth approximately $6.64 Million. The most recent transaction as insider was on Feb 18, 2024, when has been sold 13,250 shares (Common Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 195K

0.11% 3M change

6.26% 12M change

Total Value Held $6.64 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2024	BUY Exercise of conversion of derivative security	-	13,250 Added 6.2%	200,627 Common Shares
Feb 15 2024	SELL Open market or private sale	$1,617,600 $80.88 p/Share	20,000 Reduced 9.64%	187,377 Common Shares
Feb 15 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.8%	207,377 Common Shares
Jan 29 2024	SELL Open market or private sale	$3,040,000 $60.8 p/Share	50,000 Reduced 21.06%	187,377 Common Shares
Jan 29 2024	BUY Exercise of conversion of derivative security	$956,000 $19.12 p/Share	50,000 Added 17.4%	237,377 Common Shares
Jan 16 2024	SELL Open market or private sale	$1,250,000 $62.5 p/Share	20,000 Reduced 9.64%	187,377 Common Shares
Jan 16 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.8%	207,377 Common Shares
May 30 2023	SELL Open market or private sale	$1,628,250 $65.13 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
May 30 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Apr 25 2023	SELL Open market or private sale	$1,274,500 $50.98 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
Apr 25 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Mar 29 2023	SELL Open market or private sale	$1,114,250 $44.57 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
Mar 29 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Mar 13 2023	SELL Payment of exercise price or tax liability	$408,169 $43.22 p/Share	9,444 Reduced 2.38%	387,377 Common Shares
Mar 11 2023	BUY Exercise of conversion of derivative security	-	9,000 Added 2.25%	391,463 Common Shares
Mar 10 2023	BUY Exercise of conversion of derivative security	-	11,833 Added 2.96%	387,821 Common Shares
Feb 27 2023	SELL Open market or private sale	$1,212,250 $48.49 p/Share	25,000 Reduced 6.23%	375,988 Common Shares
Feb 27 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.87%	400,988 Common Shares
Feb 21 2023	SELL Payment of exercise price or tax liability	$307,560 $48.26 p/Share	6,373 Reduced 1.67%	375,988 Common Shares
Feb 18 2023	BUY Exercise of conversion of derivative security	-	13,250 Added 3.35%	382,361 Common Shares
Jan 27 2023	SELL Open market or private sale	$1,276,750 $51.07 p/Share	25,000 Reduced 6.34%	369,111 Common Shares
Jan 27 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.97%	394,111 Common Shares
Dec 28 2022	SELL Open market or private sale	$1,028,250 $41.13 p/Share	25,000 Reduced 6.34%	369,111 Common Shares
Dec 28 2022	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.97%	394,111 Common Shares
Dec 06 2022	BUY Exercise of conversion of derivative security	$105,401 $1.81 p/Share	58,233 Added 13.63%	369,111 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director